Literature DB >> 33778768

Ectopic humanized mesenchymal niche in mice enables robust engraftment of myelodysplastic stem cells.

Ghulam J Mufti1,2, Dominique Bonnet3, Syed A Mian4,5, Ander Abarrategi5, Kar Lok Kong4, Kevin Rouault-Pierre5, Henry Wood4,2, Caroline A Oedekoven5, Alexander E Smith4,2, Antoniana Batsivari5, Linda Ariza-McNaughton5, Peter Johnson6, Thomas Snoeks6.   

Abstract

Myelodysplastic syndrome (MDS) are clonal stem cell diseases characterized mainly by ineffective hematopoiesis. Here, we present an approach that enables robust long-term engraftment of primary MDS stem cells (MDS-SCs) in mice by implantation of human mesenchymal cell-seeded scaffolds. Critically for modelling MDS, where patient sample material is limiting, mononuclear bone marrow cells containing as few as 104 CD34+ cells can be engrafted and expanded by this approach with the maintenance of the genetic make-up seen in the patients. Non-invasive high-resolution ultrasound imaging shows that these scaffolds are fully perfused. Our data shows that human microenvironment but not mouse is essential to MDS-SCs homing and engraftment. Notably, the alternative niche provided by healthy donor MSCs enhanced engraftment of MDS-SCs. This study characterizes a new tool to model MDS human disease with the level of engraftment previously unattainable in mice, and offers insights into human-specific determinants of MDS-SC microenvironment.

Entities:  

Mesh:

Year:  2020        PMID: 33778768      PMCID: PMC7610449          DOI: 10.1158/2643-3230.BCD-20-0161

Source DB:  PubMed          Journal:  Blood Cancer Discov        ISSN: 2643-3230


  38 in total

1.  Childhood all blasts retain phenotypic and genotypic characteristics upon long-term serial passage in NOD/SCID mice.

Authors:  A Borgmann; C Baldy; A von Stackelberg; B Beyermann; I Fichtner; P Nürnberg; G Henze
Journal:  Pediatr Hematol Oncol       Date:  2000-12       Impact factor: 1.969

2.  Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction.

Authors:  David C Taussig; Jacques Vargaftig; Farideh Miraki-Moud; Emmanuel Griessinger; Kirsty Sharrock; Tina Luke; Debra Lillington; Heather Oakervee; Jamie Cavenagh; Samir G Agrawal; T Andrew Lister; John G Gribben; Dominique Bonnet
Journal:  Blood       Date:  2010-01-06       Impact factor: 22.113

3.  Engraftment of NOD/SCID-beta2 microglobulin null mice with multilineage neoplastic cells from patients with myelodysplastic syndrome.

Authors:  Eleni Thanopoulou; Johanne Cashman; Theodora Kakagianne; Allen Eaves; Nicholas Zoumbos; Connie Eaves
Journal:  Blood       Date:  2004-02-12       Impact factor: 22.113

4.  Targeting of the bone marrow microenvironment improves outcome in a murine model of myelodysplastic syndrome.

Authors:  Sophia R Balderman; Allison J Li; Corey M Hoffman; Benjamin J Frisch; Alexandra N Goodman; Mark W LaMere; Mary A Georger; Andrew G Evans; Jane L Liesveld; Michael W Becker; Laura M Calvi
Journal:  Blood       Date:  2015-12-04       Impact factor: 22.113

5.  Primer3--new capabilities and interfaces.

Authors:  Andreas Untergasser; Ioana Cutcutache; Triinu Koressaar; Jian Ye; Brant C Faircloth; Maido Remm; Steven G Rozen
Journal:  Nucleic Acids Res       Date:  2012-06-22       Impact factor: 16.971

6.  Clonal analysis reveals multiple functional defects of aged murine hematopoietic stem cells.

Authors:  Brad Dykstra; Sandra Olthof; Jaring Schreuder; Martha Ritsema; Gerald de Haan
Journal:  J Exp Med       Date:  2011-11-21       Impact factor: 14.307

7.  Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.

Authors:  T Haferlach; Y Nagata; V Grossmann; Y Okuno; U Bacher; G Nagae; S Schnittger; M Sanada; A Kon; T Alpermann; K Yoshida; A Roller; N Nadarajah; Y Shiraishi; Y Shiozawa; K Chiba; H Tanaka; H P Koeffler; H-U Klein; M Dugas; H Aburatani; A Kohlmann; S Miyano; C Haferlach; W Kern; S Ogawa
Journal:  Leukemia       Date:  2013-11-13       Impact factor: 11.528

8.  Flow Dynamics and HSPC Homing in Bone Marrow Microvessels.

Authors:  M Gabriele Bixel; Anjali P Kusumbe; Saravana K Ramasamy; Kishor K Sivaraj; Stefan Butz; Dietmar Vestweber; Ralf H Adams
Journal:  Cell Rep       Date:  2017-02-14       Impact factor: 9.423

9.  A humanized bone marrow ossicle xenotransplantation model enables improved engraftment of healthy and leukemic human hematopoietic cells.

Authors:  Andreas Reinisch; Daniel Thomas; M Ryan Corces; Xiaohua Zhang; Dita Gratzinger; Wan-Jen Hong; Katharina Schallmoser; Dirk Strunk; Ravindra Majeti
Journal:  Nat Med       Date:  2016-05-23       Impact factor: 53.440

10.  Cytokines increase engraftment of human acute myeloid leukemia cells in immunocompromised mice but not engraftment of human myelodysplastic syndrome cells.

Authors:  Maria Krevvata; Xiaochuan Shan; Chenghui Zhou; Cedric Dos Santos; Georges Habineza Ndikuyeze; Anthony Secreto; Joshua Glover; Winifred Trotman; Gisela Brake-Silla; Selene Nunez-Cruz; Gerald Wertheim; Hyun-Jeong Ra; Elizabeth Griffiths; Charalampos Papachristou; Gwenn Danet-Desnoyers; Martin Carroll
Journal:  Haematologica       Date:  2018-03-15       Impact factor: 9.941

View more
  4 in total

1.  The Coming of Age of Preclinical Models of MDS.

Authors:  Wei Liu; Patric Teodorescu; Stephanie Halene; Gabriel Ghiaur
Journal:  Front Oncol       Date:  2022-03-16       Impact factor: 5.738

Review 2.  Bone Marrow Niches and Tumour Cells: Lights and Shadows of a Mutual Relationship.

Authors:  Valentina Granata; Laura Crisafulli; Claudia Nastasi; Francesca Ficara; Cristina Sobacchi
Journal:  Front Immunol       Date:  2022-05-06       Impact factor: 8.786

Review 3.  The Mesenchymal Niche in Myelodysplastic Syndromes.

Authors:  Chloé Friedrich; Olivier Kosmider
Journal:  Diagnostics (Basel)       Date:  2022-07-05

Review 4.  Stem Cells in the Myelodysplastic Syndromes.

Authors:  Di Zhan; Christopher Y Park
Journal:  Front Aging       Date:  2021-07-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.